
CLAIMS

1. Use of a phorbol ester of Formula I, or a pharmaceutically-acceptable salt, isomer, or enantiomer, thereof



FORMULA I

wherein R_1 and R_2 are selected from the group consisting of hydrogen, hydroxyl, —O—C(=O)-alkyl, —O—C(=O)-lower alkenyl, —O—C(=O)-phenyl, —O—C(=O)-benzyl, and substituted derivatives thereof; and R_3 is hydrogen, —C(=O)-lower alkyl and substituted derivatives thereof, in the manufacture of a medicament for preventing or treating one or more of the effects or sequelae of stroke in a mammalian subject, wherein said medicament comprises between about 10 μg to about 1500 μg of said phorbol ester of Formula I as maximum daily dose.

2. The use of claim 1, wherein R_1 or R_2 is —O—C(=O)—C_1— C_{15} alkyl the remaining R_1 or R_2 is —O—C(=O)-lower alkyl and R_3 is hydrogen.

3. The use of claim 1, wherein the phorbol ester is phorbol 13-butyrate, phorbol 12-decanoate, phorbol 13-decanoate, phorbol 12,13-diacetate, phorbol 13,20-diacetate, phorbol 12,13-dibenzoate, phorbol 12,13-dibutyrate, phorbol 12,13-didecanoate,


phorbol 12,13-dihexanoate, phorbol 12,13-dipropionate, phorbol 12-myristate, phorbol 13-myristate, phorbol 12,13,20-triacetate, 12-deoxyphorbol 13-angelate, 12-deoxyphorbol 13-angelate 20-acetate, 12-deoxyphorbol 13-isobutyrate, 12-deoxyphorbol 13-isobutyrate-20-acetate, 12-deoxyphorbol 13-phenylacetate, 12-deoxyphorbol 13-phenylacetate 20-acetate, 12-deoxyphorbol 13-tetradecanoate, phorbol 12-tigliate 13-decanoate, 12-deoxyphorbol 13-acetate, phorbol 12-acetate, or phorbol 13-acetate.

4. The use of claim 1, further comprising use of at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation or coordinate treatment regimen with said phorbol ester of Formula I in the manufacture of the medicament to treat or prevent effects of stroke in said subject.

5. The use of claim 4, wherein the at least one secondary or adjunctive therapeutic agent is tissue plasminogen activator, an anticoagulant, a statin, fibrate, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitor, beta-blocker, anti-platelet agent, calcium channel blocker, or diuretic.

6. The use of claim 1, wherein the one or more effects of stroke are paralysis, spatial impairment, impaired judgment, left-sided neglect, memory loss, aphasia, coordination and balance problems, nausea, vomiting, cognitive impairment, perception impairment, orientation impairment, homonymous hemianopsia, or impulsivity.

7. Use of a phorbol ester of Formula I, or a pharmaceutically-acceptable salt, isomer, or enantiomer, thereof



FORMULA I

wherein R_1 and R_2 are selected from the group consisting of hydrogen, hydroxyl, —O—C(=O)-alkyl, —O—C(=O)-lower alkenyl, —O—C(=O)-phenyl, —O—C(=O)-benzyl, and substituted derivatives thereof; and R_3 is hydrogen, —C(=O)-lower alkyl and substituted derivatives thereof, in the manufacture of a medicament for preventing a stroke in a mammalian subject at risk for a stroke, wherein said medicament comprises between about 10 μg to about 1500 μg of said phorbol ester of Formula I as maximum daily dose.

8. The use of claim 7, wherein R_1 or R_2 is —O—C(=O)—C_1— C_{15} alkyl the remaining R_1 or R_2 is —O—C(=O)-lower alkyl and R_3 is hydrogen.

9. The use of claim 7, wherein the phorbol ester is phorbol 13-butyrate, phorbol 12-decanoate, phorbol 13-decanoate, phorbol 12,13-diacetate, phorbol 13,20-diacetate, phorbol 12,13-dibenzoate, phorbol 12,13-dibutyrate, phorbol 12,13-didecanoate, phorbol 12,13-dihexanoate, phorbol 12,13-dipropionate, phorbol 12-myristate, phorbol 13-myristate, phorbol 12,13,20-triacetate, 12-deoxyphorbol 13-angelate, 12-deoxyphorbol 13-angelate 20-acetate, 12-deoxyphorbol 13-isobutyrate, 12-deoxyphorbol 13-isobutyrate-20-acetate, 12-deoxyphorbol 13-phenylacetate, 12-


deoxyphorbol 13-phenylacetate 20-acetate, 12-deoxyphorbol 13-tetradecanoate, phorbol 12-tigliate 13-decanoate, 12-deoxyphorbol 13-acetate, phorbol 12-acetate, or phorbol 13-acetate.

10. The use of claim 7, further comprising use of at least one secondary or adjunctive therapeutic agent that is effective in a combinatorial formulation or coordinate treatment regimen with said phorbol ester of Formula I in the manufacture of the medicament to treat or prevent effects of stroke in said subject.



11. The use of claim 10, wherein the at least one secondary or adjunctive therapeutic agent is an anticoagulant, a statin, fibrate, angiotensin II receptor blockers, anti-platelet agent, angiotensin-converting enzyme inhibitor, beta-blocker, calcium channel blocker, or diuretic.

12. The use of Claim 1 or Claim 7, wherein the phorbol ester is 12-O-tetradecanoylphorbol-13-acetate.

13. A pharmaceutical composition comprising a phorbol ester of Formula I, or a pharmaceutically acceptable salt, isomer, or enantiomer thereof, in an amount from about 10 µg to about 1500 µg as maximum daily dose to prevent or treat one or more of effects of stroke,



FORMULA I

wherein R_1 and R_2 are selected from the group consisting of hydrogen, hydroxyl, , and substituted derivatives thereof; and R_3 is hydrogen,  and substituted derivatives thereof; and optionally at least one secondary or adjunctive therapeutic agent.

14. The composition of claim 13, wherein the phorbol ester is 12-O-tetradecanoylphorbol-13-acetate.